John Varian Net Worth

The estimated Net Worth of John Varian is at least $412 millier dollars as of 16 May 2017. Mr. Varian owns over 39,540 units of SELLAS Life Sciences Inc stock worth over $3,094 and over the last 16 years he sold SLS stock worth over $408,586. In addition, he makes $0 as Independent Director at SELLAS Life Sciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Varian SLS stock SEC Form 4 insiders trading

John has made over 35 trades of the SELLAS Life Sciences Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 39,540 units of SLS stock worth $246,730 on 16 May 2017.

The largest trade he's ever made was exercising 110,665 units of SELLAS Life Sciences Inc stock on 13 November 2013 worth over $12,173. On average, John trades about 16,750 units every 26 days since 2008. As of 16 May 2017 he still owns at least 2,344 units of SELLAS Life Sciences Inc stock.

You can see the complete history of Mr. Varian stock trades at the bottom of the page.

John Varian biography

John Varian CPA serves as Independent Director of the Company. Mr. Varian has been a director of the Company and Chair of the Audit Committee since December 2017. Mr. Varian served as Chief Executive Officer of XOMA Corporation, or XOMA, from August 2011 through December 2016 and served as a member of the board of directors of XOMA from December 2008 through May 2017. Mr. Varian served as a member of the board of directors of Versartis, Inc. (NASDAQ: VSAR) from March 2014 through October 2018, when it acquired Aravive, and the board of directors of Egalet Corporation (NASDAQ: EGLT) from June 2018 through February 2019, when it acquired the assets of Iroko. Mr. Varian previously served as Chief Operating Officer of ARYx Therapeutics, Inc. from December 2003 through August 2011. Beginning in May 2000, Mr. Varian was Chief Financial Officer of Genset S.A. in France, where he was a key member of the team negotiating Genset’s sale to Serono S.A. in 2002. From 1998 to 2000, Mr. Varian served as Senior Vice President, Finance and Administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation’s Chief Financial Officer from 1997 until 1998. From 1991 until 1997, Mr. Varian served as the VP Finance and Chief Financial Officer of Anergen Inc. Mr. Varian was an Audit Principal/Senior Manager at Ernst & Young LLP from 1987 until 1991, where he focused on life sciences. Mr. Varian was also a founding committee member of Bay Bio and a former chairman of the Association of Bioscience Financial Officers International Conference. Mr. Varian holds a B.B.A. from Western Michigan University. He is a Certified Public Accountant.

How old is John Varian?

John Varian is 59, he's been the Independent Director of SELLAS Life Sciences Inc since 2017. There are 3 older and 12 younger executives at SELLAS Life Sciences Inc. The oldest executive at SELLAS Life Sciences Group Inc is David Scheinberg, 64, who is the Director.

What's John Varian's mailing address?

John's mailing address filed with the SEC is C/O SELLAS LIFE SCIENCES GROUP, INC.,, 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036.

Insiders trading at SELLAS Life Sciences Inc

Over the last 7 years, insiders at SELLAS Life Sciences Inc have traded over $74,616 worth of SELLAS Life Sciences Inc stock. The most active insiders traders include John Varian, Jane Wasman et David A Scheinberg. On average, SELLAS Life Sciences Inc executives and independent directors trade stock every 205 days with the average trade being worth of $6,842. The most recent stock trade was executed by Angelos M. Stergiou on 5 December 2022, trading 6,494 units of SLS stock currently worth $16,949.

What does SELLAS Life Sciences Inc do?

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.

Complete history of Mr. Varian stock trades at Acorda Therapeutics Inc, XOMA Royalty et SELLAS Life Sciences Inc

SELLAS Life Sciences Inc executives and stock owners

SELLAS Life Sciences Inc executives and other stock owners filed with the SEC include:

• Angelos Stergiou,
  President, Chief Executive Officer, Director
• Dr. Angelos M. Stergiou M.D., ScD h.c.,
  Founder, Pres, CEO & Director
• Barbara Wood,
  Executive Vice President, General Counsel, Corporate Secretary
• Barbara A. Wood,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Dragan Cicic M.D., MBA,
  Sr. VP of Clinical Devel.
• John Burns,
  Interim Principal Accounting Officer, Vice President - Finance, Corporate Controller
• Dr. Dragan Cicic,
  Sr. VP of Clinical Devel.
• Jane Wasman,
  Independent Chairman of the Board
• John Varian,
  Independent Director
• Robert Van Nostrand,
  Independent Director
• David Scheinberg,
  Director
• Dragan Cicic,
  Senior Vice President - Clinical Development
• Jörg W. Breitkopf,
  Head of Clinical Operations
• Robert M. Francomano,
  Sr. VP & Chief Commercial Officer
• John Thomas Burns CPA,
  Sr. VP of Fin. & Chief Accounting Officer
• David D. Moser,
  VP of Legal Affairs
• Jörg W. Breitkopf,
  Head of Clinical Operations
• Dr. Christopher R. Shackleton,
  Director of Clinical and Bus. Operations
• Martin G. Baum,
  Chief Operating Officer
• John Thomas Burns CPA, CPA,
  VP of Fin., Corp. Controller & Chief Accounting Officer
• Fabio Lopez,
  Director
• Nicholas J. Sarlis,
  Chief Medical Officer and SVP
• Robert Francomano,
  Chief Commercial Officer
• Fabio Eqc Private Markets S...,
  
• Stephen F Ghiglieri,
  Director
• Gregory M Torre,
  CRO and SVP
• Fabio Eqc Private Markets S...,
  
• Gene Mack,
  CFO and Treasurer
• Katherine Bach Kalin,
  Director